share_log

維亞生物：截至二零二三年十二月三十一日止年度之 年度業績公告以及本公司組織章程大綱和 章程細則之建議修訂

VIVA BIOTECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION OF THE COMPANY

香港交易所 ·  Mar 28 08:06
Summary by Moomoo AI
維亞生物科技控股集團公布截至2023年12月31日止年度業績，收入及毛利分別錄得9.4%及9.5%的下降。淨虧損顯著收窄至人民幣99.8百萬元，較去年同期的人民幣504.2百萬元大幅改善。經調整非國際財務報告準則淨利潤由去年同期的人民幣133.9百萬元虧損轉為人民幣208.8百萬元盈利。報告期內，維亞生物成功引入淡馬錫等戰略投資人，完成約2.25億美金的融資，並清償全部可轉債，改善資產負債表和現金流。CRO業務在中短期受全球生物醫藥投融資放緩影響，但中長期發展前景良好。CDMO產能持續擴建，CMC項目數增加。公司未來將進一步加強對高質量CMC項目的BD及導流，推動CMC業務實現盈虧平衡。
維亞生物科技控股集團公布截至2023年12月31日止年度業績，收入及毛利分別錄得9.4%及9.5%的下降。淨虧損顯著收窄至人民幣99.8百萬元，較去年同期的人民幣504.2百萬元大幅改善。經調整非國際財務報告準則淨利潤由去年同期的人民幣133.9百萬元虧損轉為人民幣208.8百萬元盈利。報告期內，維亞生物成功引入淡馬錫等戰略投資人，完成約2.25億美金的融資，並清償全部可轉債，改善資產負債表和現金流。CRO業務在中短期受全球生物醫藥投融資放緩影響，但中長期發展前景良好。CDMO產能持續擴建，CMC項目數增加。公司未來將進一步加強對高質量CMC項目的BD及導流，推動CMC業務實現盈虧平衡。
VIA BIOTECHNOLOGY HOLDINGS ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH REVENUES AND GROSS PROFIT DECLINES OF 9.4% AND 9.5% RESPECTIVELY. Net loss narrowed significantly to RMB99.8 million, a significant improvement from RMB504.2 million in the same period last year. Adjusted Non-International Financial Reporting Criteria net profit translated from a loss of RMB133.9 million in the same period last year to a profit of RMB208.8 million. During the reporting period, ViaBio successfully brought in strategic investors such as Tammasy, completed approximately US$2.25 million in financing and cleared all transferable debt, improving its balance sheet and cash flow. The CRO business has been affected in the medium to short term by slowing global biopharmaceutical financing, but the prospects are good in the medium and long term. CDMO CAPACITY CONTINUES TO EXPAND AND THE NUMBER OF CMC PROJECTS INCREASES. In the future, the Company will further strengthen the BD and conduit for high-quality CMC projects to drive the CMC business to achieve profit and loss balance.
VIA BIOTECHNOLOGY HOLDINGS ANNOUNCED ITS RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023, WITH REVENUES AND GROSS PROFIT DECLINES OF 9.4% AND 9.5% RESPECTIVELY. Net loss narrowed significantly to RMB99.8 million, a significant improvement from RMB504.2 million in the same period last year. Adjusted Non-International Financial Reporting Criteria net profit translated from a loss of RMB133.9 million in the same period last year to a profit of RMB208.8 million. During the reporting period, ViaBio successfully brought in strategic investors such as Tammasy, completed approximately US$2.25 million in financing and cleared all transferable debt, improving its balance sheet and cash flow. The CRO business has been affected in the medium to short term by slowing global biopharmaceutical financing, but the prospects are good in the medium and long term. CDMO CAPACITY CONTINUES TO EXPAND AND THE NUMBER OF CMC PROJECTS INCREASES. In the future, the Company will further strengthen the BD and conduit for high-quality CMC projects to drive the CMC business to achieve profit and loss balance.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more